
    
      This is a postmarketing patient safety study in the FDA indicated population of patients
      receiving Plenaxis速. On a quarterly basis, patients enrolled in the Plenaxis速 Experience
      Study will have their charts audited to record the number of immediate-onset systemic
      allergic reactions that may occur while receiving Plenaxis速. The study will close when 2,000
      patients have been enrolled. If immediate onset allergic reactions occur, patients may be
      eligible to enroll in a second protocol (skin testing in patients who experience an immediate
      onset allergic reaction). Collection of all immediate-onset systemic allergic reactions will
      continue for each patient enrolled in the study until the patient discontinues Plenaxis速 for
      any reason, the patient withdraws consent to continue in the study or the patient is lost to
      follow-up.
    
  